Luxembourg: The European Court of Auditors handed Europe’s Beating Cancer Plan a lukewarm five-year verdict in Special Report 07/2026, with a sharp focus on the gap between Brussels-level ambition and Member State delivery. The plan carries a four-billion-euro envelope, anchors ten flagship initiatives and has reached more than ninety percent of its planned actions, according to the Commission’s own February 2025 review. The auditors do not contest the activity. They contest whether the activity is translating into outcomes that can be measured by the EU’s own targets for 2030.
The numbers tell the sharpest part of the story. HPV vaccination of girls under fifteen averages sixty-four percent across the bloc, against an EU 2030 target of ninety percent. The spread runs from seven percent in Bulgaria to ninety-one percent in Portugal. In Bulgaria, Estonia and Latvia the rate has actually fallen over the last decade despite the plan’s prevention pillar being designed precisely to lift it. Breast cancer screening participation tells a parallel story. Denmark, Finland, Sweden and Slovenia sit above seventy-five percent. Romania, Cyprus, Slovakia, Hungary, Bulgaria, Latvia and Poland sit below forty percent. More than half of Member States, including Germany, France and Italy, recorded falling participation even as the plan’s flagship awareness instruments rolled out.
The auditors flag four structural problems. Insufficient Member State ownership of national strategies that were supposed to translate the EU plan into operational targets. Duplication of projects across the EU4Health programme, the Horizon Europe Mission on Cancer, the Cancer Imaging Initiative and the relaunched Code Against Cancer. Uneven progress on screening across cancer types, with cervical and colorectal screening lagging breast cancer even where uptake is high. And weaknesses in plan design itself, including the absence of quantified targets for several actions, missing deadlines and inconsistent indicators that make comparison across years and Member States unreliable.
Two of those problems are operational. The other two are political. Ownership and indicator architecture are choices that Member States and the Commission make together. The auditors’ recommendation is to harden the indicators through the Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases, with a clear hierarchy between core indicators that Member States must report against and supplementary indicators that remain voluntary. The Commission has accepted the recommendation in principle but pushed back against any move to make reporting binding before the plan’s 2028 mid-term refresh.
The relaunched Code Against Cancer published in February 2026 is the most concrete prevention deliverable since the plan began. Drafted by more than sixty European public health experts over four years, the Code expanded its remit to cover ultra-processed food, air pollution, breastfeeding and alcohol intake alongside the long-standing focus on tobacco, weight, physical activity and sun exposure. Air pollution is the most contested addition. It draws an explicit line from the revised Ambient Air Quality Directive that enters application in stages from 2030 to the cancer burden, and that link will land in capitals still negotiating transposition.
Diagnostic and treatment infrastructure is the other axis. The Cancer Imaging Initiative now connects more than sixty hospital data sets across nineteen Member States, but the auditors flag that the federated infrastructure has not yet delivered the cross-border clinical use cases that the design promised. Cancer Mission projects launched in 2024 and 2025 are still in early phase, and the Commission’s spring 2026 call cycle on UNCAN.eu and microbiome research sits at the research end of the plan rather than the screening and access end where the data gap is largest.
Quality of life for survivors is the fourth plan pillar and the one where Member State variance is highest. The auditors’ country chapters point to the Smart Health Card and the European Health Data Space as the levers that could narrow the gap, but the EHDS regulation is still in its phased application window and the Smart Health Card pilot has not moved beyond seven Member States. Patient organisations welcomed the audit’s emphasis on this pillar while pushing for the next plan iteration to include enforceable benchmarks on return-to-work support and on long-term follow-up care.
The political read in Brussels is that the report does not threaten the plan’s continuation. It does threaten the assumption that volume of activity equals progress. A revised plan architecture is now expected in the second half of 2026, anchored by a tighter indicator set, by clearer Member State commitments on screening uptake, and by a more honest separation of what the EU funds, what national systems deliver and what gets measured. The next test arrives in the autumn rule of law and European Semester cycle, where the indicator hardening will run head-on into capitals that resist binding country recommendations on health system performance.




